{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:38Z","timestamp":1761514838408,"version":"3.37.3"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Summary:<\/jats:title>\n               <jats:p>In this issue, Pulsipher and colleagues used next-generation sequencing to detect leukemia-specific sequences following tisagenlecleucel therapy of acute lymphoblastic leukemia. A challenge for the field currently is to identify which patients will have therapy failure and to do so early enough to allow planning for further treatment, for example, stem cell transplantation. Detection of disease below the standard detection level for this technique (less than one per million cells) at day 28 was associated with poorer outcomes and potentially therefore could be used to identify those that might benefit from adjunctive therapies.<\/jats:p>\n               <jats:p>See related article by Pulsipher et al. p. 66.<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-21-0199","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T09:35:28Z","timestamp":1638351328000},"page":"2-4","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rare Sequences Make Sense of CAR T-cell Therapy Outcomes"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-2946","authenticated-orcid":false,"given":"Sara","family":"Ghorashian","sequence":"first","affiliation":[{"name":"1Department of Haematology Great Ormond Street Hospital for Children, London, United Kingdom."},{"name":"2Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Bartram","sequence":"additional","affiliation":[{"name":"1Department of Haematology Great Ormond Street Hospital for Children, London, United Kingdom."},{"name":"2Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2023021314442101300_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2023021314442101300_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134472","article-title":"Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"2023021314442101300_bib3","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023021314442101300_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"2023021314442101300_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/bmt.2017.16","article-title":"Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL","volume":"52","author":"Kotrova","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023021314442101300_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"2023021314442101300_bib7","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023021314442101300_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"2023021314442101300_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2023021314442101300_bib10","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/1\/2\/3269451\/2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/1\/2\/3269451\/2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T14:44:37Z","timestamp":1676299477000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/3\/1\/2\/675476\/Rare-Sequences-Make-Sense-of-CAR-T-cell-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,1]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0199","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"type":"print","value":"2643-3230"},{"type":"electronic","value":"2643-3249"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}